The estimated Net Worth of Matthew R Plooster is at least $43.6 Tausend dollars as of 18 May 2022. Mr. Plooster owns over 5,000 units of Zevra Therapeutics Inc stock worth over $43,575 and over the last 10 years he sold KMPH stock worth over $0. In addition, he makes $0 as Independent Director at Zevra Therapeutics Inc.
Matthew has made over 1 trades of the Zevra Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of KMPH stock worth $24,800 on 18 May 2022.
The largest trade he's ever made was buying 5,000 units of Zevra Therapeutics Inc stock on 18 May 2022 worth over $24,800. On average, Matthew trades about 333 units every 0 days since 2015. As of 18 May 2022 he still owns at least 7,500 units of Zevra Therapeutics Inc stock.
You can see the complete history of Mr. Plooster stock trades at the bottom of the page.
Matthew R. Plooster serves as Independent Director of the Company. Mr. Plooster co-founded Bridgepoint Investment Banking, a division of Bridgepoint Holdings, LLC , where he has served as a managing director since March 2012. Previously, Mr. Plooster worked as an investment banker from 2004 to 2012 at various firms including, Morgan Stanley and Deutsche Bank. Mr. Plooster received his Certificate in Business Excellence from Columbia Business School and his B.A. degree from the University of Chicago. Our Board believes that Mr. Plooster’s experience as an investor in and transaction experience with healthcare companies, as well as other board of director’s experience, provides him with the qualifications and skills to serve as a director of our company.
Matthew Plooster is 38, he's been the Independent Director of Zevra Therapeutics Inc since 2011. There are 12 older and 2 younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.
Matthew's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney und Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include: